A randomised phase III trial of carboplatin compared with docetaxel in BRCA1/2 mutated and pre-specified triple negative breast cancer “BRCAness” subgroups: the TNT Trial

BRCA1/2 germline mutations predispose to breast cancer (gBRCA-BC) by impairing homologous recombination (HR) causing genomic instability. HR also repairs DNA lesions caused by platinums and PARP inhibitors. Triple Negative Breast Cancers (TNBC) harbour sub-populations with BRCA1/2 mutations, hypothe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Med
Main Authors: Tutt, Andrew, Tovey, Holly, Cheang, Maggie Chon U, Kernaghan, Sarah, Kilburn, Lucy, Gazinska, Patrycja, Owen, Julie, Abraham, Jacinta, Barrett, Sophie, Barrett-Lee, Peter, Brown, Robert, Chan, Stephen, Dowsett, Mitchell, Flanagan, James M, Fox, Lisa, Grigoriadis, Anita, Gutin, Alexander, Harper-Wynne, Catherine, Hatton, Matthew Q, Hoadley, Katherine A, Parikh, Jyoti, Parker, Peter, Perou, Charles M, Roylance, Rebecca, Shah, Vandna, Shaw, Adam, Smith, Ian E, Timms, Kirsten M, Wardley, Andrew M, Wilson, Gregory, Gillett, Cheryl, Lanchbury, Jerry S, Ashworth, Alan, Rahman, Nazneen, Harries, Mark, Ellis, Paul, Pinder, Sarah E, Bliss, Judith M
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6372067/
https://ncbi.nlm.nih.gov/pubmed/29713086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41591-018-0009-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados